Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anagrelide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B known ✓ | Q13370 | 20/20 | 0.85 |
| ▸ | PDE3A known ✓ | Q14432 | 20/20 | 0.85 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | PDE2A | O00408 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anagrelide SCHEMBL5060881 | 0.92 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL318593 | 0.91 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1568712 | 0.91 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL729172 | 0.90 | PDE3B (0.94) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL16335881 | 0.89 | PDE3B (0.87) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| SCHEMBL13885751 | 0.82 | PDE3B (0.75) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1571355 | 0.78 | PDE3B (0.64) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1027237 | 0.78 | PDE3B (0.71) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| SCHEMBL10605681 | 0.76 | PDE3B (0.70) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| SCHEMBL10324347 | 0.76 | PDE3B (0.70) | PDE3BPDE3AP2RY12MEN1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115003279-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-112955124-A | Oral film compositions and dosage forms having precise active dissolution profiles | 阿奎蒂夫疗法公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-112585690-A | System and method for producing individualized individual unit doses containing a pharmaceutically active substance | 阿奎斯蒂弗医疗股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-105744983-B | Device and method for sustained release of therapeutic agents of low water solubility in solubilizing agents | 纳米医学系统公司 | 2019-12-27 | — | — | CN | disclosed |